[Pulmonary hypertension in adults with congenital heart disease in light of the 2022-ESC-PAH guidelines - Part II: Supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ transplantation, special management (shunt lesions, left ventricular disorders, univentricular hearts), interventions, intensive care, follow-up, future perspectives]

The number of adults with congenital heart defects (CHD) is steadily rising and amounts to approximately 360,000 in Germany. CHD is often associated with pulmonary hypertension (PH), which may develop early in untreated CHD. Despite timely treatment of CHD, PH not infrequently persists or recurs in older age and is associated with significant morbidity and mortality.The revised European Society of Cardiology/European Respiratory Society 2022 guidelines for the diagnosis and treatment of PH represent a significant contribution to the optimized care of those affected. However, the topic of "adults with congenital heart disease" is addressed only relatively superficial in these guidelines. Therefore, in the present article, this topic is commented in detail from the perspective of congenital cardiology.

• Kaemmerer, H.
• Diller, G. P.
• Achenbach, S.
• Dähnert, I.
• Eichstaedt, C. A.
• Eicken, A.
• Freiberger, A.
• Freilinger, S.
• Geiger, R.
• Gorenflo, M.
• Grünig, E.
• Hager, A.
• Huntgeburth, M.
• Kaemmerer-Suleiman, A. S.
• Kozlik-Feldmann, R.
• Lammers, A. E.
• Nagdyman, N.
• Michel, S.
• Schmidt, K. H.
• Uebing, A.
• von Scheidt, F.
• Apitz, C.